Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Desmopressin for Bleeding Related to Low Body Temperature

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by The University of Hong Kong.
Recruitment status was:  Not yet recruiting
Information provided by:
The University of Hong Kong Identifier:
First received: May 13, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.

Condition Intervention Phase
Hypothermia Induced Impairment of Primary Haemostasis
Drug: desmopressin
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • closure time on PFA-100 [ Time Frame: 3 hours ]

Estimated Enrollment: 48
Study Start Date: June 2009
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: desmopressin 1.5 Drug: desmopressin
single desmopressin subcutaneous injection, 1.5mcg
Active Comparator: desmopressin 3 Drug: desmopressin
single desmopressin subcutaneous injection, 3mcg
Active Comparator: desmopressin 15 Drug: desmopressin
single desmopressin subcutaneous injection, 15mcg
Placebo Comparator: placebo Drug: placebo
saline subcutaneous


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

1. Healthy volunteers

Exclusion Criteria:

  1. Any known platelet or coagulation disorder.
  2. Pregnant or lactating women.
  3. Known chronic liver or renal disease.
  4. Coronary artery, carotid artery or peripheral artery disease
  5. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations.
  6. Smoker or alcohol user
  7. Mentally incapable of providing informed consent
  8. Students or junior staff members who had direct working relationship with the PI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00902057

Contact: Kwok F.J. Ng, MBChB, MD, MBA, FANZCA, FHKAM (852) 28553303

China, Hong Kong
The University of Hong Kong Not yet recruiting
Hong Kong, Hong Kong, China, HKSAR
Contact: Kwok F.J. Ng, MBChB, MD, FANZCA, FHKAM, MBA    (852) 28553303   
Principal Investigator: Kwok F. J. Ng, MD,MBA         
Sponsors and Collaborators
The University of Hong Kong
  More Information

Responsible Party: Dr Kwok Fu Jacobus Ng, Department of Anaesthesiology, the Univeristy of Hong Kong Identifier: NCT00902057     History of Changes
Other Study ID Numbers: UW 09-088
Study First Received: May 13, 2009
Last Updated: May 13, 2009

Additional relevant MeSH terms:
Body Temperature Changes
Signs and Symptoms
Deamino Arginine Vasopressin
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs processed this record on May 25, 2017